Aurinia Pharmaceuticals Inc

AUPHNASDAQ NMS - GLOBAL MARKET

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company is headquartered in Edmonton, Alberta. The company went IPO on 2001-07-16. The firm is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The firm is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. The company sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The firm sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Aurinia Pharmaceuticals Inc.